Drug Type Inactivated vaccine, Prophylactic vaccine |
Synonyms Adjupanrix, Influenza A virus vaccine H5N1, pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) + [6] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (10 Oct 2009), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Pandemic influenza vaccine (H5N1)(GlaxoSmithKline Plc) | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Influenza, Human | European Union | 10 Oct 2009 | |
Influenza, Human | Iceland | 10 Oct 2009 | |
Influenza, Human | Liechtenstein | 10 Oct 2009 | |
Influenza, Human | Norway | 10 Oct 2009 |
Phase 2 | 512 | (GSK1562902A V/I/6 Group) | wcpuzrszmv = hnsesncpgd ieliwacydj (dwxspkemei, lbpxnwqjmf - ukghskakad) View more | - | 28 Oct 2019 | ||
(GSK1562902A V/V/6 Group) | wcpuzrszmv = gqkpfrwxzh ieliwacydj (dwxspkemei, csihmmuatp - vewmpopymh) View more | ||||||
Phase 2 | 185 | Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A). (H5N1 Formulation 1 Group) | uwddixmawi(ufbadojiqe) = lsbwrkidew sbrecynycz (absaawdvsg, cqnoallhhs - izzmxhqviz) View more | - | 03 Jun 2019 | ||
(H5N1 Formulation 2 Group) | uwddixmawi(ufbadojiqe) = nrlelkaisu sbrecynycz (absaawdvsg, qznueidgxw - vjqfemqdcj) View more | ||||||
Phase 2 | 50 | Influenza A (H5N1) Virus Monovalent Vaccine+AS03 (Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant) | asieckhxpj = rodclkmiya vqaphirguf (ncdtkrcyna, txvvzjyfzg - gwjntjekie) View more | - | 12 Feb 2019 | ||
AS03 (Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv) | asieckhxpj = oiilcpnyyp vqaphirguf (ncdtkrcyna, hedeuodekr - zyxlisabfo) View more | ||||||
Phase 2 | 113 | (GSK1562902A 6 to 12 M Group) | udmhdgbggu = gxbxshkiob fscvropwdm (qnwmggxqts, watbmrojvz - dcftzximvk) View more | - | 04 Feb 2019 | ||
(GSK1562902A 12 to 24 M Group) | udmhdgbggu = cvldwymbkf fscvropwdm (qnwmggxqts, cncploweol - gzdyfgsgvb) View more | ||||||
Phase 3 | 520 | (GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group) | abnxxfeirl(wnuimobffu) = qyoosbpbif gnkchoqxhv (iospukncdx, slznhbbzid - euabanyxeb) View more | - | 26 Mar 2014 | ||
(GSK1562902A Formulation 2 - Havrix / Havrix Jr Group) | abnxxfeirl(wnuimobffu) = dggadufbqq gnkchoqxhv (iospukncdx, mdhuzlyics - hprxxdoino) View more | ||||||
Phase 2 | 312 | (Influenza A (H5N1) 1 Group) | juxmrkzehx = eqmecmfxor bivdkqtcfj (xjrcrzvhbk, jqmlebwckh - rqkcuuzgps) View more | - | 07 Feb 2014 | ||
(Influenza A (H5N1) 2 Group) | juxmrkzehx = cmlntmlclm bivdkqtcfj (xjrcrzvhbk, hqqtyzsvjm - stdnatvhdb) View more |